Key features and details
- Sensitivity: 100 ng/ml
- Range: 100 ng/ml - 3000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameCetuximab ELISA Kit
See all Cetuximab kits
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15%
Sample typeSerum, Plasma
Assay typeSandwich (quantitative)
Range100 ng/ml - 3000 ng/ml
Sample specific recovery Sample type Average % Range Serum 85% - 115%
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Note: Cetuximab ELISA kit ab237648 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Cetuximab in the sample or standard. Results of samples can be determined directly using the standard curve.
Storage instructionsStore at +4°C. Please refer to protocols.
Components 96 tests Micro ELISA Plate 1 unit Cetuximab Standard S1 1 x 0.3ml Cetuximab Standard S2 1 x 0.3ml Cetuximab Standard S3 1 x 0.3ml Cetuximab Standard S4 1 x 0.3ml Cetuximab Standard S5 1 x 0.3ml Cetuximab Standard S6 1 x 0.3ml Cetuximab Standard S7 1 x 0.3ml Assay Buffer 2 x 50ml HRP-conjugate Probe 1 x 12ml TMB substrate 1 x 12ml Stop Solution 1 x 12ml Wash buffer (20X) 1 x 50ml Plate sealers 2 units
RelevanceCetuximab is a chimeric monoclonal antibody of the immunoglobulin G1 (IgG1) and FDA-approved epidermal growth factor receptor (EGFR) inhibitor. Preclinical studies have shown that cetuximab enhances the antitumour effects of chemotherapy as well as radiotherapy by inhibiting cell proliferation, angiogenesis and metastasis and by promoting apoptosis is used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab blocks growth factor-induced activation of the downstream mitogen-activated protein kinase, inhibiting cell proliferation. It also decreases angiogenic factors, inhibits tumor-cell invasion and metastasis via downregulation of matrix metalloproteinases (MMPs) and VEGF, and promotes apoptosis by upregulating apoptotic protein, Bax, with the help of other chemotherapeutic agents.
ab237648 has not yet been referenced specifically in any publications.